In brief
Dr. Tracy Beth Hoeg has been dismissed from her role as acting director of the FDA’s drug center, a position she held since December. This development follows the resignation of FDA Commissioner Marty Makary and highlights ongoing turmoil within the agency amid criticism from political allies. Hoeg’s abrupt exit has garnered attention, especially as it relates to her connection with safety evaluations of vaccines and antidepressants, raising questions about regulatory processes and leadership continuity in a critical federal agency.
WASHINGTON (Flux Daily News) — In a significant shift within the Food and Drug Administration (FDA), Dr. Tracy Beth Hoeg has been removed from her role leading the agency's drug program. Sources indicate she has been dismissed following increasing scrutiny over the safety of major therapeutic interventions including antidepressants and COVID-19 vaccines.
Hoeg, who was appointed as acting director in December, expressed her feelings on social media, stating she was 'fired,' yet conveyed a sense of closure, saying, 'I learned so much and leave with no regrets.'
The change arrives amidst a series of high-profile departures, including that of FDA Commissioner Marty Makary, who resigned earlier this week. This influx of leadership changes adds to concerns about safety evaluation protocols and transparency within the agency.
Dr. Mike Davis, previously deputy director, will succeed Hoeg, while the agency also announced Karim Mikhail as the new acting director of the vaccines center. These alterations in leadership come after sustained pressure from President Donald Trump's political allies, particularly anti-abortion groups and vaping lobbyists, who have expressed frustration with the FDA's regulatory direction.
Hoeg's tenure saw her involved in controversial discussions surrounding vaccine safety and regulatory practices, particularly relating to antidepressants and COVID-19 vaccinations. Critics have questioned her approach, noting her connections with players outside government who have been vocal critics of traditional public health measures. The fallout surrounding Hoeg’s dismissal raises doubts about the FDA's stability and commitment to rigorous scientific evaluation, particularly as it faces significant public health challenges.
